Skip to main content Help with accessibility Skip to main navigation

July 2020 updates to the website

The website has now been updated following July's LSCMMG

The following Drugs have been added/updated:

Fremanezumab - For preventing migraine (TA 631)

Ustekinumab - For treating moderately to severely active ulcerative colitis (TA 633)

Avatrombopag - For treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA 626)

The following guidelines have been added/updated:

Guidelines for the prescribing of nutritional supplements post bariatric surgery - Position Statement - Update

Assessing suitability for strong Opioid use pathway - Guidance - New

The following Items will be ratified and added to the website following Joint Committee of CCGs (JCCCG) Meeting:

Rifaximin - Second line antibacterial treatment for the treatment of Small Intestinal Bacterial Overgrowth

Linezolid - Pneumonia, skin and soft-tissue infections

Psoriasis: LSCMMG Biologic and High Cost Drug Commissioning Pathway - Update

Over the Counter Items that Should not be Routinely Prescribed in Primary Care Policy - Update